CYP2D6Genetic Polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas

Abstract

Aim: In previous CYP2D6 genotyping studies in Mexican–Amerindians a very low frequency of poor metabolizers (PMs) has been reported. Moreover, ultrarapid metabolizers (UMs) status has only been analyzed in some groups from Northern Mexico. Materials & methods: In the present study we evaluated the hypothesis of low frequency of PMs in Mexican–Amerindians in Southern Mexican populations from Chiapas (Lacandones [ML] vs Mestizos [MM]). The frequency of UMs is also reported. CYP2D6 alleles *2, *3, *4, *5, *6, *10, *17, *35 and *41 and copy number variations were analyzed in 154 ML and 100 MM healthy volunteers. Results: The PM frequency was 0% in MLs and 1% in MMs, and for UMs was 2.6% in MLs and 3% in MMs. Conclusion: The present data support previous findings reporting a very low frequency of CYP2D6 PMs in Mexican–Amerindians. Furthermore, the predicted UM phenotype in both MMs and MLs was lower than those reported for most Mexican populations.

Keywords::

• CYP2D6
• Lacandones
• Mexican–Mestizo
• pharmacogenetics

Financial & competing interest disclosure

This study was supported by Consejo Nacional de Ciencia y Tecnología de México (CONACYT #167261) and by Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+I) and Fondo Social Europeo of the European Union (FEDER), Instituto de Salud Carlos III-FIS Research Grants (PI10/02758; PI10/02010), by AEXCID Cooperación Extremeña of the Junta de Extremadura (13IA001) to SIFF and coordinated in the Network Red Iberoamericana de Farmacogenética y Farmacogenómica (RIBEF). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Additional information

Funding

This study was supported by Consejo Nacional de Ciencia y Tecnología de México (CONACYT #167261) and by Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+I) and Fondo Social Europeo of the European Union (FEDER), Instituto de Salud Carlos III-FIS Research Grants (PI10/02758; PI10/02010), by AEXCID Cooperación Extremeña of the Junta de Extremadura (13IA001) to SIFF and coordinated in the Network Red Iberoamericana de Farmacogenética y Farmacogenómica (RIBEF). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.